Prosecution Insights
Last updated: May 29, 2026
Application No. 17/525,060

COMPOSITIONS AND THERAPEUTIC METHODS

Non-Final OA §112
Filed
Nov 12, 2021
Priority
Mar 30, 2016 — provisional 62/315,144 +1 more
Examiner
BAKSHI, PANCHAM
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
AyuVis Research, Inc.
OA Round
3 (Non-Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
882 granted / 1146 resolved
+17.0% vs TC avg
Strong +30% interview lift
Without
With
+30.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
45 currently pending
Career history
1220
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
42.1%
+2.1% vs TC avg
§102
12.8%
-27.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1146 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 02/16/2026 has been entered. Status of the Application Claims 1-9 are pending in the application, of which Claims 5 and 7-9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-4 and 6 are under current examination. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(a): IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim(s) 1-4 and 6 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The subject matter of instant claim 1, filed on 02/16/2026 is not properly described in the application as filed. In particular, there was no indication in original specification as filed or in canceled “biotin linked with a linker” (there is a support for a specific linker that is attached in compounds of claim 6 but not to any broad linker with any chemical structure) and therefore raise doubt as to possession of the claimed invention at the time of filing. Applicant is required to cancel the new matter in the reply to this Office Action. Since the dependent claims doesn’t cure the above deficiency, claims 2-4 and 6 are also rejected. Response to Arguments Applicant’s remarks, TD and amendment, as filed on 02/16/2026, have been fully considered but not found persuasive. Applicant argument is moot in view of new rejection as set forth above. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached on 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Nov 12, 2021
Application Filed
Mar 27, 2025
Non-Final Rejection mailed — §112
Sep 25, 2025
Response Filed
Oct 15, 2025
Final Rejection mailed — §112
Dec 15, 2025
Response after Non-Final Action
Feb 16, 2026
Request for Continued Examination
Feb 24, 2026
Response after Non-Final Action
Mar 10, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637407
Process For The Preparation of Mixed Polyol-Carboxylic Acid EstersE
2y 10m to grant Granted May 26, 2026
Patent 12630569
METHOD FOR PRODUCING ORGANIC SILICON COMPOUND HAVING KETIMINE STRUCTURE
3y 8m to grant Granted May 19, 2026
Patent 12617748
A PROCESS FOR RECYCLING OF POLYETHYLENE TEREPHTHALATE (PET) WASTE
2y 11m to grant Granted May 05, 2026
Patent 12612385
COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS
2y 5m to grant Granted Apr 28, 2026
Patent 12595353
PLASTICIZER COMPOSITION AND RESIN COMPOSITION COMPRISING THE SAME
3y 0m to grant Granted Apr 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.1%)
2y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1146 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month